



## Measurable Residual Disease in Cancer

Guest Editors:

### **Prof. Dr. Krzysztof Jamrozik**

Department of Hematology,  
Transplantation and Internal  
Medicine, Medical University of  
Warsaw, Banacha 1a, 02-097  
Warsaw, Poland

### **Dr. Bartosz Pula**

Department of Hematology,  
Institute of Hematology and  
Transfusion Medicine, 02-776  
Warsaw, Poland

Deadline for manuscript  
submissions:

**closed (30 November 2023)**

### **Message from the Guest Editors**

Dear Colleagues,

Measurable residual disease (MRD) refers to the presence of cancer cells below the threshold of detection when using conventional methods of assessing response to treatment.

In this Special Issue, a panel of internationally recognized experts will focus on the current and future role of MRD in cancer with respect to MRD assessment techniques, MRD as a prognostic/predictive factor or therapeutic target as well as MRD-based directions in the anticancer drugs development.

Potential topics include, but are not limited to:

- Systematic reviews on the current role of MRD in particular types of cancer
- Novel methods of MRD assessment and MRD standardization efforts in cancer
- Design and results of clinical trials testing MRD-driven treatment strategies
- Original studies reporting treatment of disease at MRD or subclonal levels in clinical practice
- Significance of genomic and spatial heterogeneity of MRD
- Role of tumor microenvironment regarding MRD persistence/eradication
- MRD as surrogate endpoint for new anti-cancer drug development and approval



[mdpi.com/si/130366](https://mdpi.com/si/130366)

Prof. Dr. Krzysztof Jamrozik

Dr. Bartosz Pula

*Guest Editors*

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)